Byetta vs Mounjaro

exenatide (GLP-1 receptor agonist) vs tirzepatide (Dual GIP and GLP-1 receptor agonist) — a complete side-by-side comparison.

AstraZenecaEli Lilly

Byetta weight loss

2.8%

Mounjaro weight loss

22.5%

Byetta dosing

Twice daily (within 60 min before meals)

Mounjaro dosing

Once weekly

Reviewed by Dr. Elena Vance, DOLast reviewed 4 sources cited

Quick Summary

Byetta (exenatide) and Mounjaro (tirzepatide) are both incretin-based therapies. In clinical trials, Mounjaro showed greater weight loss (22.5% vs 2.8%).

See the comparison table below for detailed side-by-side data.

Byetta vs Mounjaro: Full Comparison

FeatureByetta(exenatide)Mounjaro(tirzepatide)
Active Ingredientexenatidetirzepatide
Drug ClassGLP-1 receptor agonistDual GIP and GLP-1 receptor agonist
ManufacturerAstraZenecaEli Lilly
FDA Approved2005-04-282022-05-13
Approved Indications
  • Type 2 diabetes mellitus (adjunct to diet and exercise)
  • Type 2 diabetes mellitus (adjunct to diet and exercise)
Routesubcutaneous injectionsubcutaneous injection
FrequencyTwice daily (within 60 min before meals)Once weekly
Starting Dose5 mcg twice daily2.5 mg weekly
Maintenance Dose10 mcg twice daily5 mg, 10 mg, or 15 mg weekly
Max Dose10 mcg twice daily15 mg weekly
Weight Loss (%)2.8%22.5%
A1C Reduction0.8%2.4%
Key TrialAC2993 Phase 3 (30 weeks)SURMOUNT-1 (72 weeks)
List Price$800-$900/month$1,023-$1,176/month
With Insurance$25-$100/month (varies by plan)$25-$150/month (varies by plan)
Savings CardLimited savings programs available$25/month (Lilly savings card, commercially insured)

Side Effects: Byetta vs Mounjaro

Side EffectByettaMounjaro
Nausea44%12-18%
Vomiting13%5-9%
Diarrhea13%12-17%
Headache9%Not reported
Dizziness9%Not reported
Dyspepsia6%5-8%
Jittery feeling4%Not reported
Pancreatitis (rare)<1%<0.5%
Decreased appetiteNot reported5-11%
ConstipationNot reported6-7%
Abdominal painNot reported5-6%
Injection site reactionNot reported3-5%

Severity scale: 1 (mild) to 5 (serious). Based on FDA prescribing information and clinical trial data.

Related Comparisons

Frequently Asked Questions

Sources & References

  1. Byetta FDA prescribing information
  2. Mounjaro FDA prescribing information
  3. DeFronzo RA et al., Diabetes Care 2005;28:1092-1100.
  4. Jastreboff AM et al., N Engl J Med 2022;387:327-340. FDA prescribing information.

This content is for informational purposes only and is not medical advice. Always consult your healthcare provider before making medication decisions. See our full medical disclaimer.